Brain-Health Company IXICO Ready To Seize Pharma's Digital Health Opportunities
Executive Summary
Brain-health company IXICO is ready to seize pharma's digital health opportunities by expanding into the companion digital health product sector. Last year the company partnered with Biogen to pilot its digital platform Assessa with the drug TYSABRI.
You may also be interested in...
IXICO Aims To Scale Up In 2018
Brain health imaging company IXICO has outlined a five-point plan to scale business in a bid to deliver double digit revenue growth. With a new CEO at the helm, the UK company is looking to expand its network of pharma partners, increase its penetration of the clinical trials market and target later-stage clinical phases with its digital technologies.
Pharma Friend? IXICO Seeks To Boost MS Drug Sales With Brain Health Tech
IXICO has struck a partnership with a major pharma player to help improve clinical outcomes of the latter’s blockbuster drug for multiple sclerosis – which will hopefully lead to increased sales – by adding the use of IXICO’s Assessa digital brain health monitoring technology to better manage a serious and potentially fatal side effect of the therapy.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.